324 related articles for article (PubMed ID: 16240334)
1. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
Anandarajah AP; Schwarz EM
J Cell Biochem; 2006 Feb; 97(2):226-32. PubMed ID: 16240334
[TBL] [Abstract][Full Text] [Related]
2. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
Tanaka S; Nakamura K; Takahasi N; Suda T
Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
[TBL] [Abstract][Full Text] [Related]
3. RANKL-RANK signaling in osteoclastogenesis and bone disease.
Wada T; Nakashima T; Hiroshi N; Penninger JM
Trends Mol Med; 2006 Jan; 12(1):17-25. PubMed ID: 16356770
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
Aubin JE; Bonnelye E
Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
[TBL] [Abstract][Full Text] [Related]
5. Osteoclast precursors, RANKL/RANK, and immunology.
Xing L; Schwarz EM; Boyce BF
Immunol Rev; 2005 Dec; 208():19-29. PubMed ID: 16313338
[TBL] [Abstract][Full Text] [Related]
6. Rheumatic diseases: the effects of inflammation on bone.
Walsh NC; Crotti TN; Goldring SR; Gravallese EM
Immunol Rev; 2005 Dec; 208():228-51. PubMed ID: 16313352
[TBL] [Abstract][Full Text] [Related]
7. RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis.
Ritchlin CT; Schwarz EM; O'Keefe RJ; Looney RJ
J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):276-84. PubMed ID: 15615495
[TBL] [Abstract][Full Text] [Related]
8. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
Yeung RS
J Rheumatol; 2004 May; 31(5):844-6. PubMed ID: 15124240
[No Abstract] [Full Text] [Related]
9. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
Kostenuik PJ
Curr Opin Pharmacol; 2005 Dec; 5(6):618-25. PubMed ID: 16188502
[TBL] [Abstract][Full Text] [Related]
10. [Clinical implications of new insights into the regulation of bone resorption].
Lems WF; Bijlsma JW
Ned Tijdschr Geneeskd; 2005 Jul; 149(30):1664-7. PubMed ID: 16104110
[TBL] [Abstract][Full Text] [Related]
11. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
Giuliani N; Colla S; Rizzoli V
Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.
Blair JM; Zhou H; Seibel MJ; Dunstan CR
Nat Clin Pract Oncol; 2006 Jan; 3(1):41-9. PubMed ID: 16407878
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG).
Hofbauer LC
Ann Endocrinol (Paris); 2006 Apr; 67(2):139-41. PubMed ID: 16639364
[No Abstract] [Full Text] [Related]
14. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
Collin-Osdoby P
Circ Res; 2004 Nov; 95(11):1046-57. PubMed ID: 15564564
[TBL] [Abstract][Full Text] [Related]
15. Evidence of a role for RANKL in the development of myeloma bone disease.
De Leenheer E; Mueller GS; Vanderkerken K; Croucher PI
Curr Opin Pharmacol; 2004 Aug; 4(4):340-6. PubMed ID: 15251126
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.
Hofbauer LC; Schoppet M
JAMA; 2004 Jul; 292(4):490-5. PubMed ID: 15280347
[TBL] [Abstract][Full Text] [Related]
17. Bone cancer pain and the role of RANKL/OPG.
Clohisy DR; Mantyh PW
J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):293-300. PubMed ID: 15615497
[TBL] [Abstract][Full Text] [Related]
18. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Ann N Y Acad Sci; 2006 Apr; 1068():225-33. PubMed ID: 16831922
[TBL] [Abstract][Full Text] [Related]
19. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].
Ferrer Cañabate J; Tovar I; Martínez P
An Med Interna; 2002 Aug; 19(8):385-88. PubMed ID: 12244784
[No Abstract] [Full Text] [Related]
20. RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse.
Mori H; Kitazawa R; Mizuki S; Nose M; Maeda S; Kitazawa S
Histochem Cell Biol; 2002 Mar; 117(3):283-92. PubMed ID: 11914926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
